

POST-TRAUMATIC STRESS DISORDER (PTSD): AN OVERVIEW**Suresh Rewar***

Department of Pharmaceutics, Rajasthan University of Health Sciences, Jaipur, Rajasthan.

Article Received on
19 March 2015,Revised on 08 April 2015,
Accepted on 29 April 2015***Correspondence for****Author****Suresh Rewar**Department of
Pharmaceutics, Rajasthan
University of Health
Sciences, Jaipur,
Rajasthan.**ABSTRACT**

Post-traumatic stress disorder (PTSD) is a complex mental disorder with psychological and emotional components, caused by exposure to single or repeated extreme traumatic events found in war, terrorist attacks, natural or man-caused disasters, and by violent personal assaults and accidents. In recent years, armed conflicts in the Middle East have resulted in high rates of exposure to traumatic events. Despite the increasing demand of mental health care provision, ongoing violence limits conventional approaches of mental health care provision. Internet-based interventions for posttraumatic stress disorder (PTSD) have proved feasible and effective in Western countries, but their applicability and efficacy in war and conflict regions remains unknown. Despite clinical studies and improved understanding of the

mechanisms of cellular damage, prevention and treatment strategies for patients with PTSD remain unsatisfactory. Posttraumatic stress disorder is a prevalent mental health problem associated with substantial psychiatric morbidity. To develop an improved plan for treating and impeding progression of PTSD, it is important to identify underlying biochemical changes that may play key role in the initiation and progression of these disorders.

KEYWORDS: Post-Traumatic Stress Disorder (PTSD), Epidemiology, Diagnosis, CBT, EMDR.

INTRODUCTION

During the last 30 years, there has been a substantial increase in the study of posttraumatic stress disorder (PTSD). Post-traumatic stress disorder (PTSD) is a complex disorder which is caused by exposure to single or repeated traumatic events such as those found in war, terrorism, in natural or human-caused disasters, and in violent personal assaults, such as rape, mugging, domestic violence and accidents.^[1] Individuals with PTSD have persistent fear

memory and often feel emotionally numb. If left untreated, PTSD can be life-threatening, as it is often linked with substance abuse and severe depression. In recent decades, war and human rights violations in the Middle East have led to high rates of exposure to traumatic events and to a correspondingly high incidence of posttraumatic stress disorder (PTSD) in the region.^[2] With the invasion of Iraq by the US-led coalition forces in 2002, exposure to traumatizing events increased dramatically, with suicide bombers killing significantly more civilians than coalition soldiers.^[3] A study of 289,328 Iraq and Afghanistan veterans who were first-time users of Veterans Affairs (VA) health care between 2002 and 2008 showed that 22% of veterans were diagnosed with PTSD and 17% were diagnosed with depression.^[4-5] People with post-traumatic stress disorder (PTSD) often suffer from memory disturbances. In particular, previous studies suggest that PTSD patients perform atypically on tests of directed forgetting, which may be mediated by an altered emotional appraisal of the presented material.^[6] PTSD process has emerged from recent studies of the “freeze” response or tonic immobility. Briefly, tonic immobility is an involuntary, reflexive state, characterized by apparent physical paralysis, muscular rigidity, and inability to vocalize. The freeze response is more complex in humans, however, as it may be triggered by symbolic events such as the perception that a situation is inescapable.^[7-8] Traumatic events, PTSD and psychosis appear to have several interactions. The presence of a comorbid PTSD has been found to have a negative impact on the course and prognosis of the psychotic disorder and the combination of psychosis and PTSD appears to be associated with poorer social functioning and greater risk of relapsing in psychosis.^[9-11] Considering these findings and being aware that PTSD in general is associated with forms of non-effective coping, more abuse of alcohol and drugs, negative self esteem, negative expectations of other people, and a greater risk of exposure to future potentially traumatic events^[12], it becomes clear that trauma exposure is associated with impairment and major health problems in patients with psychosis, creating a burden for both patients and society.^[13-14] Providing medical or mental health care in regions of war and ongoing violent conflict often puts mental health professionals at great risk. Very few studies have reported on mental health care services provided for survivors of war in developing countries. Although their results have been encouraging, these approaches are available to only small numbers of people, are relatively costly, and require health professionals to be located on site.^[15-16] Internet-based delivery of psychotherapeutic interventions has become increasingly established in the Western world. In particular, interventions developed for patients with PTSD have been shown to produce significant

reductions in PTSD symptoms and in associated psychopathology, such as depression and anxiety.^[17-22]

EPIDEMIOLOGY AND RISK FACTORS

The wars in Iraq and Afghanistan have renewed attention to the mental health effects of deployment, including PTSD, and, as a result, there is a large amount of research on the prevalence of PTSD in service personnel who were deployed to these countries.^[23] Ahmadi et al. studied 150 cases of CIVs and 156 healthy men in 2002. They showed that in the veteran group 30 cases (20%) had severe stress disorders, 87 cases (58%) moderate and 3 mild stress disorders.^[24] Hashemian et al. conducted a cross sectional study on 153 habitants of three cities in the West Azarbaijan province of Iran in 2004. The characteristics of locations were as follows: Sardasht as a high intensity of both chemically and conventional warfare exposed town, Rabat as a non-chemically attached town and Oshnavieh, a town with lower intensity conventional warfare.^[25] Posttraumatic stress disorder (PTSD) occurs in an estimated 8% of men and 20% of women who are exposed to traumatic events. PTSD is a trauma- and stress-related disorder associated with significant psychosocial morbidity, substance abuse, and other negative physical health outcomes.^[26] Between 1986 and 2005, none of the 10,000 participants in randomized clinical trials for major mental disorders were American Indians and Alaska Natives.^[27] Risk factors associated with progression to chronic PTSD are not well understood. Although there may be a genetic component in a small percentage of cases, environmental and biologic factors (e.g., poor psychosocial support, history of trauma, history of mental health problems) are also important risk factors.^[28] Resiliency development and positive psychology programs have been emphasized for persons with high-risk professions, but there is no evidence that these programs prevent PTSD.^[29]

CLINICAL FEATURES AND SYMPTOMS

The symptoms of PTSD include unwanted re-experiencing of the traumatic memory (flashbacks, nightmares, triggered emotional responses), passive and active avoidance of the experience (emotional numbing, avoidance of discussions about the traumatic event).^[1] Many of the other symptoms of PTSD, such as hyperarousal, avoidance, and numbing, overlap with other mental disorders, such as generalized anxiety disorder, panic disorder, and depression. Thus it is important to delineate whether the person is re-experiencing symptoms in relation to a traumatic event.^[30-31] When patients are repeatedly confronted with their feared memories and at the same time experience a feeling of safety, over time this procedure can

lead to reduced anxiety and aversive behavior associated with the fear memory. This process is called fear extinction and substantial progress has been made to understand the underlying molecular mechanisms.^[32]

ETIOLOGY

PTSD is conceptualized as a failure of recovery caused in part by altered fear learning; i.e., the failure to extinguish behavioral responses to stimuli associated with the trauma.^[33] Following a trauma, the symptoms of PTSD are almost universal; however, many people are able to eventually confront fearful stimuli such as memories, reminders, or visual cues with a gradual decrease of fear.^[34-35] When this decrease does not occur, people tend to develop cognitive and avoidance strategies in an attempt to avoid distressing emotions. Subsequently, these strategies interfere with the extinction of fear by limiting exposure to safe reminders. Alterations in fear learning involve the hippocampus, amygdala, and prefrontal cortex. The hippocampus appears to be involved in the ability to recall safe episodes when faced with fearful stimuli. Research has shown that hippocampal volumes are decreased in patients with PTSD, but this may be a risk factor rather than a sequella.^[36-37]

CAUSES

Genes: Currently, many scientists are focusing on genes that play a role in creating fear memories. Understanding how fear memories are created may help to refine or find new interventions for reducing the symptoms of PTSD.^[38] For example, PTSD researchers have pinpointed genes that make: Stathmin, a protein needed to form fear memories. In one study, mice that did not make stathmin were less likely than normal mice to “freeze,” a natural, protective response to danger, after being exposed to a fearful experience. They also showed less innate fear by exploring open spaces more willingly than normal mice. GRP (gastrin releasing peptide) a signaling chemical in the brain released during emotional events. In mice, GRP seems to help control the fear response, and lack of GRP may lead to the creation of greater and more lasting memories of fear. Researchers have also found a version of the 5HTTLPR gene, which controls levels of serotonin-a brain chemical related to mood that appears to fuel the fear response. Like other mental disorders, it is likely that many genes with small effects are at work in PTSD.^[39-40]

Brain Areas: Studying parts of the brain involved in dealing with fear and stress also helps researchers to better understand possible causes of PTSD. One such brain structure is the amygdala, known for its role in emotion, learning, and memory. The amygdala appears to be

active in fear acquisition, or learning to fear an event (such as touching a hot stove), as well as in the early stages of fear extinction, or learning not to fear.^[41] Storing extinction memories and dampening the original fear response appears to involve the prefrontal cortex (PFC) area of the brain, involved in tasks such as decision making, problem solving, and judgment. Certain areas of the PFC play slightly different roles. For example, when it deems a source of stress controllable, the medial PFC suppresses the amygdala an alarm center deep in the brainstem and controls the stress response.^[42-44] The ventromedial PFC helps sustain long term extinction of fearful memories, and the size of this brain area may affect its ability to do so.^[45] Individual differences in these genes or brain areas may only set the stage for PTSD without actually causing symptoms. Environmental factors, such as childhood trauma, head injury, or a history of mental illness, may further increase a person's risk by affecting the early growth of the brain. Also, personality and cognitive factors, such as optimism and the tendency to view challenges in a positive or negative way, as well as social factors, such as the availability and use of social support, appear to influence how people adjust to trauma. More research may show what combinations of these or perhaps other factors could be used someday to predict who will develop PTSD following a traumatic event.^[46]

DIAGNOSIS

Assessment: The diagnosis of posttraumatic stress disorder (PTSD), from its introduction into the psychiatric nosology in DSM-III to the latest edition DSM-IV, attests to the centrality of the stressor criterion in the definition of this disorder. The DSM-IV definition of the PTSD stressor is a clear departure from previous versions.^[47] various scales to measure the severity and frequency of PTSD symptoms exist. The Clinician-Administered PTSD Scale (CAPS-1) appears to satisfy these standards most uniformly.^[48] Standardized screening tools such as Trauma Screening Questionnaire^[49] and PTSD Symptom Scale^[50] can be used to detect possible symptoms of posttraumatic stress disorder and suggest the need for a formal diagnostic assessment.

DSM-5 Criteria for PTSD diagnosis: "A" stressor criterion specifies that a person has been exposed to a catastrophic event involving actual or threatened death or injury, or a threat to the physical integrity of him/herself or others (such as sexual violence). Indirect exposure includes learning about the violent or accidental death or perpetration of sexual violence to a loved one. Exposure through electronic media (e.g. televised images the 9/11 attacks on the World Trade Center) is not considered a traumatic event. it is important to understand that

one new feature of DSM-5 is that all of these symptoms must have had their onset or been significantly exacerbated after exposure to the traumatic event.^[51] Specifies criteria for the diagnosis of post-traumatic stress disorder. These include.^[52]:

- Exposure to a traumatic event that involved actual or threatened death or injury (to self or others) or a threat to physical integrity,
- The person's response to the traumatic life event must have involved intense fear, helplessness, or horror,
- Persistent re-experiencing of the event (criteria specify that the person must have one or more of the re-experiencing symptoms),
- Persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness (three or more avoidance symptoms),
- Two or more persistent symptoms of arousal,
- Duration of symptoms must last more than one month, and
- Symptoms must cause clinically significant distress or impaired functioning.

PREVENTION

The first generation of research on PTSD prevention focused primarily on universal prevention (i.e., the delivery of interventions to all people exposed to trauma, regardless of symptoms or risk of developing PTSD). However, based on evidence that 1) debriefing interventions for all people exposed to particular traumas did not reduce PTSD and 2) most people exposed to trauma experience symptoms of PTSD but do not develop PTSD and its attendant functional impairment, a new model of PTSD prevention, targeted prevention, has generated a second generation of PTSD prevention research. The goal of targeted prevention is to identify, from among all people exposed to trauma, those individuals who are at high risk of developing the disorder of PTSD and then intervene only with those at high risk^[53] Preclinical considerations suggest that treatment with a beta-adrenergic blocker following an acute psychologically traumatic event may reduce subsequent posttraumatic stress disorder (PTSD) symptoms. Modest benefits have been seen from early access to cognitive behavioral therapy, as well as from some medications such as propranolol.^[54] Critical incident stress management has been suggested as a means of preventing PTSD, but subsequent studies suggest the likelihood of its producing iatrogenic outcomes.^[55] The World Health Organization recommends against the use of benzodiazepines and antidepressants in those having experienced trauma. Common practices in the aftermath of trauma such as debriefing and benzodiazepines need to be carefully considered, taking into account their potential harm

to the spontaneous recovery process, and the trajectory of PTSD, and not only judging them according to their immediate (comforting) effects.^[56]

TREATMENTS

The main treatments for posttraumatic stress disorder (PTSD) are psychotherapy and medication. Traumatic events can be very difficult to come to terms with, but confronting your feelings and seeking professional help is often the only way of effectively treating PTSD. It is possible for PTSD to be successfully treated many years after the traumatic event occurred, which means it is never too late to seek help.^[46,51,57]

Assessment: Before having treatment for PTSD, a detailed assessment of your symptoms will be carried out to ensure treatment is tailored to your individual needs. Your GP will often carry out an initial assessment, but you will be referred to a mental health specialist for further assessment and treatment if you have had symptoms of PTSD for more than four weeks or your symptoms are severe.^[57] There are a number of mental health specialists you may see if you have PTSD, such as: a psychologist an expert in how the mind works, a community psychiatric nurse a nurse who specializes in mental healthcare, a psychiatrist a mental health specialist who diagnoses and treats mental health conditions.^[46,57]

Watchful waiting: If you have mild symptoms of PTSD, or you have had symptoms for less than four weeks, an approach called watchful waiting may be recommended. Watchful waiting involves carefully monitoring your symptoms to see whether they improve or get worse. It is sometimes recommended because 2 in every 3 people who develop problems after a traumatic experience will get better without treatment within a few weeks. If watchful waiting is recommended, you should have a follow up appointment within one month.^[46,57]

Psychotherapy: If you have PTSD that requires treatment, psychotherapy is usually recommended first. A combination of psychotherapy and medication may be recommended if you have severe or persistent PTSD. Psychotherapy is a type of therapy often used to treat emotional problems and mental health conditions such as PTSD, depression, anxiety and obsessive compulsive disorder. The treatment is carried out by trained mental health professionals who will listen to you and help you come up with effective strategies to resolve your problems. The two main types of psychotherapy used to treat people with PTSD are described below.^[46,52,57]

Cognitive behavioural therapy (CBT): Cognitive behavioural therapy (CBT) is a type of therapy that aims to help you manage your problems by changing how you think and act. Trauma focused CBT uses a range of psychological treatment techniques to help you come to terms with the traumatic event. For example, your therapist may ask you to confront your traumatic memories by thinking about your experience in detail. During this process your therapist will help you cope with any distress you feel, while identifying any unhelpful thoughts or misrepresentations you have about the experience. By doing this, your therapist can help you gain control of your fear and distress by changing the negative way you think about your experience, such as feeling that you are to blame for what happened or fear that it may happen again. You may also be encouraged to gradually restart any activities you have avoided since your experience, such as driving a car if you had an accident. You will usually have 8-12 weekly sessions of trauma focused CBT, although fewer may be needed if the treatment starts within one month of the traumatic event. Sessions where the trauma is discussed will last for around 90 minutes.^[46,52,57-58]

Eye movement desensitization and reprocessing (EMDR): Eye movement desensitization and reprocessing (EMDR) is a relatively new treatment (Figure: 1) that has been found to reduce the symptoms of PTSD. EMDR involves making side to side eye movements, usually by following the movement of your therapist's finger, while recalling the traumatic incident. It is not clear exactly how EMDR works, but it may help the malfunctioning part of the brain (the hippocampus) to process distressing memories and flashbacks so that their influence over your mind is reduced.^[46,52,57]




Figure.1: Diseases treated by EMDR ^[59]

Medication: Antidepressants such as paroxetine, mirtazapine, amitriptyline or phenelzine are sometimes used to treat PTSD in adults. Of these medications, paroxetine is the only one licensed specifically for the treatment of PTSD. However, mirtazapine, amitriptyline and phenelzine have also been found to be effective and are often recommended as well.^[46,52,57] However, these medications will only be used if

- You choose not to have trauma focused psychological treatment.
- Psychological treatment would not be effective because there is an ongoing threat of further trauma (such as domestic violence).
- You have gained little or no benefit from a course of trauma focused psychological treatment
- You have an underlying medical condition, such as severe depression, that significantly affects your ability to benefit from psychological treatment.

Amitriptyline or phenelzine will only be used under the supervision of a mental health specialist. Antidepressants can also be prescribed to reduce any associated symptoms of depression and anxiety and to help with sleeping problems. However, they are not usually prescribed for people younger than 18 unless recommended by a specialist. If medication for PTSD is effective, it will usually be continued for a minimum of 12 months before being gradually withdrawn over the course of four weeks or longer. If a medication is ineffective at reducing your symptoms, your dosage may be increased. Before prescribing a medication, your doctor should inform you about possible side effects that you may have while taking it, along with any possible withdrawal symptoms when the medication is withdrawn. For example, common side effects of paroxetine include feeling sick, blurred vision, constipation and diarrhoea. Possible withdrawal symptoms associated with paroxetine include sleep disturbances, intense dreams, anxiety and irritability.^[46,52]

Children and young people

For children and young people with PTSD, trauma focused CBT is usually recommended. This will normally involve a course of 8-12 sessions that have been adapted to suit the child's age, circumstances and level of development. Where appropriate, treatment will include consulting with and involving the child's family. Treatment with medication is not usually recommended for children and young people with PTSD.^[46] Individual trauma- focused CBT is an effective treatment for PTSD in children and young people.^[60]

CONCLUSIONS

The traumatized PTSD brain accumulates damage over time. Neurons in the hippocampus, amygdala and other parts of the brain are destroyed by glucocorticoids. Chemical imbalances and their corresponding effects (as well as the opposite effects) may occur. Adrenergics and glucocorticoids, along with serotonin and other moieties, affect immune, chemical and structural responses to produce short- and long-term effects that we recognize as sequelae of PTSD. In a naturalistic study we observed a significant reduction in PTSD scores and functional impairment following treatment. These improvements were maintained at 6 month follow-up. It may be helpful to take a closer look at combining individual trauma-focused cognitive behaviour therapy and group sessions when treating veterans with PTSD.

ACKNOWLEDGEMENTS

The authors reported no conflict of interest. The authors alone are responsible for the content and writing of the paper and no funding has been received on this work. Ethical Approval was not required.

REFERENCES

1. Prasad KN, Bondy SC. Common biochemical defects linkage between post-traumatic stress disorders, mild traumatic brain injury (TBI) and penetrating TBI; Brain Res. 2015; 1599C:103-114.
2. Al-Jawadi AA, Abdul-Rhman S. Prevalence of childhood and early adolescence mental disorders among children attending primary health care centers in Mosul, Iraq: a cross-sectional study. BMC Public Health 2007; 7:274.
3. Hicks MH, Dardagan H, Guerrero SG, Bagnall PM, Sloboda JA, Spagat M. Violent deaths of Iraqi civilians, 2003-2008: analysis by perpetrator, weapon, time, and location. PLoS Med 2011; 8(2):e1000415.
4. Yang et al. Core modular blood and brain biomarkers in social defeat mouse model for post traumatic stress disorder; BMC Syst Biol. 2013; 7:80.
5. Hicks MH, Dardagan H, Bagnall PM, Spagat M, Sloboda JA. Casualties in civilians and coalition soldiers from suicide bombings in Iraq, 2003-10: a descriptive study. Lancet 2011; 378 (9794):906-914.
6. Baumann M, Zwissler B, Schalinski I, Ruf-Leuschner M, Schauer M, Kissler J. Directed forgetting in post-traumatic-stress-disorder: a study of refugee immigrants in Germany; Front Behav Neuro sci. 2013; 7:94.

7. Marx BP, Forsyth JP, Gallup GG, Lexington JM. FuséT, Tonic immobility as an evolved predator defence: implications for sexual assault survivors. *Clin Psychol Sci Practice* 2008; 15(1): 74-90.
8. Hageraars MA, Oitzl M, Roelofs K .Updating freeze: aligning animal and human research. *Neuro sci Bio behave Rev* 2014; 47:165-76.
9. Lysaker PHP, Buck KDMAB, LaRocco VAM: Clinical and psychosocial significance of trauma history: in the treatment of schizophrenia. *J Psychosoc Nurs Ment Health Serv* 2007, 45:44-51.
10. Morrison AP, Frame L, Larkin W: Relationships between trauma and psychosis: a review and integration. *Br J Clin Psychol* 2003; 42:331-353.
11. Mueser KT, Lu W, Rosenberg SD, Wolfe R: The trauma of psychosis: posttraumatic stress disorder and recent onset psychosis. *Schizophr Res* 2010; 116:217-227.
12. Mueser KT, Rosenberg SD, Goodman LA, Trumbetta SL: Trauma, PTSD, and the course of severe mental illness: an interactive model. *Schizophr Res* 2002; 53:123–143.
13. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ: The economic burden of anxiety disorders in the 990s. *J Clin Psychiatry* 1999; 60:427-435.
14. Hong J, Windmeijer F, Novick D, Haro JM, Brown J: The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. *Prog Neuropsychopharmacol Biol Psychiatry* 2009; 33:835-841.
15. Schaal S, Elbert T, Neuner F. Narrative exposure therapy versus interpersonal psychotherapy. A pilot randomized controlled trial with Rwandan genocide orphans. *Psychother Psychosom* 2009; 78(5):298-306.
16. Neuner F, Onyut PL, Ertl V, Odenwald M, Schauer E, Elbert T. Treatment of posttraumatic stress disorder by trained lay counselors in an African refugee settlement: a randomized controlled trial. *J Consult Clin Psychol* 2008 Aug; 76(4):686-694.
17. Benight CC, Ruzek JI, Waldrep E. Internet interventions for traumatic stress: a review and theoretically based example. *J Trauma Stress* 2008; 21(6):513-520.
18. Litz BT, Engel CC, Bryant RA, Papa A. A randomized, controlled proof-of-concept trial of an Internet-based, therapist-assisted self-management treatment for posttraumatic stress disorder. *Am J Psychiatry* 2007; 164(11):1676-1683.
19. Klein B, Mitchell J, Abbott J, Shandley K, Austin D, Gilson K, et al. A therapist-assisted cognitive behavior therapy internet intervention for posttraumatic stress disorder: pre-,

- post- and 3-month follow-up results from an open trial. *J Anxiety Disord* 2010; 24(6):635-644.
20. Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PMG. Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. *J Consult Clin Psychol* 2003; 71(5):901-909.
21. Knaevelsrud C, Wagner B, Karl A, Mueller J. New treatment approaches: integrating new media in the treatment of war and torture victims. *Torture* 2007; 17(2):67-78.
22. Wagner B, Knaevelsrud C, Maercker A. Internet-based cognitive-behavioral therapy for complicated grief: a randomized controlled trial. *Death Stud* 2006; 30(5):429-453.
23. LA et al. Posttraumatic stress disorder post Iraq and Afghanistan: prevalence among military subgroups; *Can J Psychiatry*. 2014; 59(9):468-79.
24. Ahmadi, Reshadatjoo M, Karami GhR. [Evaluation of PTSD in Sardasht survivors of chemical warfare.] *Urmia Med J* 2010; 21(1): 1-9.
25. Hashemian F, Khoshnood K, Desai MM, Falahati F, Kasl S, Southwick S. Anxiety, depression, and posttraumatic stress in Iranian survivors of chemical warfare. *JAMA* 2006; 296(5): 560-6.
26. Warner CH, Warner CM, Appenzeller GN, Hoge CW. Identifying and managing posttraumatic stress disorder; *Am Fam Physician*. 2013; 88(12):827-34.
27. Miranda J, et al. State of the science on psychosocial interventions for ethnic minorities. *Annu Rev Clin Psychol*. 2005; 1:113-42.
28. True WR, Rice J, Eisen SA, et al. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. *Arch Gen Psychiatry*. 1993; 50(4):257-264.
29. Lester PB, McBride S, Bliese PD, Adler AB. Bringing science to bear: an empirical assessment of the Comprehensive Soldier Fitness program. *Am Psychol*. 2011; 66(1):77-81.
30. Sareen J et al. Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment; *Can J Psychiatry*. 2014; 59(9):460-7.
31. Griffin GD, Charron D, Al-Daccak R. Posttraumatic stress disorder: revisiting adrenergic, glucocorticoids, immune system effects and homeostasis; *Clin Transl Immunology*. 2014; 3 (11): e27.
32. Bahari-Javan S, Sananbenesi F, Fischer A. Histone-acetylation: a link between Alzheimer's disease and post-traumatic stress disorder? *Front Neurosci*. 2014; 8:160.

33. Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions; *Ann N Y Acad Sci.* 2003;1008:112-21.
34. Forbes D. et.al. Trauma at the hands of another: distinguishing PTSD patterns following intimate and nonintimate interpersonal and noninterpersonal trauma in a nationally representative sample; *J Clin Psychiatry.* 2014; 75(2):147-53.
35. Pfaltz MC, Michael T, Meyer AH, Wilhelm FH. Re-experiencing symptoms, dissociation, and avoidance behaviors in daily life of patients with PTSD and patients with panic disorder with agoraphobia; *J Trauma Stress.* 2013; 26(4):443-50.
36. Bonne OB, Brandes D, Gilboa A, Gomori JM, Shenton ME, Pitman RK, et al. Longitudinal MRI study of hippocampal volume in trauma survivors with PTSD. *American Journal of Psychiatry* 2001; 158(8):1248-1251.
37. Wimalawansa SJ. Mechanisms of developing post-traumatic stress disorder: new targets for drug development and other potential interventions; *CNS Neurol Disord Drug Targets.* 2014; 13(5):807-16.
38. Afifi TO, Asmundson GJ, Taylor S, Jang KL. The role of genes and environment on trauma exposure and posttraumatic stress disorder symptoms: a review of twin studies; *Clin Psychol Rev.* 2010; 30(1): 101-12.
39. Segman RH, Shalev AY. Genetics of posttraumatic stress disorder; *CNS Spectr.* 2003; 8(9):693-8.
40. Brummett BH, Siegler IC, Ashley-Koch A, Williams RB. Effects of 5HTTLPR on cardiovascular response to an emotional stressor; *Psychosom Med.* 2011; 73(4):318-22.
41. Suvak MK, Barrett LF. Considering PTSD from the Perspective of Brain Processes: A Psychological Construction Approach; *J Trauma Stress.* 2011; 24(1): 3-24.
42. Adolphs R. The neurobiology of social cognition; *Curr Opin Neurobiol.* 2001 Apr; 11(2):231-9.
43. Bar M. The proactive brain: using analogies and associations to generate predictions. *Trends Cogn Sci.* 2007 Jul; 11(7):280-9.
44. Wager TD, Barrett LF, Bliss-Moreau E, Lindquist K, Duncan S, Kober H, Mize J. The neuroimaging of emotion. In: Lewis M, Haviland-Jones JM, Barrett LF, editors. *The handbook of emotion.* 3. New York, NY: Guilford Press; 2008. pp. 249–271.
45. Vogt BA Pain and emotion interactions in subregions of the cingulate gyrus; *Nat Rev Neurosci.* 2005 Jul; 6(7):533-44.

46. The National Institute of Mental Health (NIMH), Post-Traumatic Stress Disorder (PTSD); Available at: <http://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd/index.shtml> [Accessed: March 27, 2015]¹
47. Breslau N, Kessler RC. "The stressor criterion in DSM-IV posttraumatic stress disorder: an empirical investigation". *Biol. Psychiatry*. 2001; 50 (9): 699-704.
48. Blake DD, et.al. "The development of a Clinician Administered PTSD Scale". *J Trauma Stress*. 1995 8 (1): 75-90.
49. Brewin CR, Rose S, Andrews B, Green J, Tata P, McEvedy C, Turner S, Foa EB. "Brief screening instrument for post traumatic stress disorder". *British Journal of Psychiatry*. 2002; 181: 158-162.
50. Foa EB, Cashman L, Jaycox L, Perry K. "The validation of a self report measure of posttraumatic stress disorder: the Posttraumatic Diagnostic Scale". *Psychological Assessment*. 1997; 9 (4): 445-451.
51. U.S. Department of Veterans Affairs, PTSD History and Overview - PTSD_ National Center for PTSD Available at: <http://www.ptsd.va.gov/professional/PTSD-overview/ptsd-overview.asp> [Accessed: March 27, 2015]¹
52. Department of Veterans Affairs Employee Education System and the National Center for PTSD: Post-Traumatic Stress Disorder: Implications for Primary Care: Diagnostic; Available at: <http://www.publichealth.va.gov/docs/vhi/posttraumatic.pdf> [Accessed: March 29, 2015]¹
53. Gartlehner G et al. Interventions for the Prevention of Posttraumatic Stress Disorder (PTSD) in Adults After Exposure to Psychological Trauma [Internet]; Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr.
54. Pitman RK., Sanders KM., Zusman RM., et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. *Biol Psychiatry*. 2002; 51:189-192.
55. Mayou RA, Ehlers A, Hobbs M (2000). "Psychological debriefing for road traffic accident victims. Three year follow up of a randomised controlled trial". *Br J Psychiatry* 176 (6): 589-93.
56. Zohar J, Juven-Wetzler A, Sonnino R, Cwikel-Hamzany S, Balaban E, Cohen H. New insights into secondary prevention in post-traumatic stress disorder; *Dialogues Clin Neurosci*. 2011; 13 (3):301-9.
57. NHS Choices (www.nhs.uk), Post-traumatic stress disorder (PTSD) Available at: <http://www.nhs.uk/conditions/post-traumatic-stress-disorder/pages/introduction.aspx> [Accessed: March 27, 2015]¹

58. Nilamadhab Kar. Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review; Neuropsychiatr Dis Treat. 2011; 7:167-181.
59. Afsaneh Zarghi, Alireza Zali, and Mehdi Tehranidost, Methodological Aspects of Cognitive Rehabilitation with Eye Movement Desensitization and Reprocessing (EMDR); Basic Clin Neurosci. Winter, 2013; 4(1): 97-103.
60. Smith P, Yule W, Perrin S, Tranah T, Dalgleish T, Clark DM. Cognitive-behavioral therapy for PTSD in children and adolescents: a preliminary randomized controlled trial; J Am Acad Child Adolesc Psychiatry. 2007; 46(8):1051-61.